Laverock Therapeutics Awarded Over £2.2M in Innovation Grants for AI‑Powered Platform and Non‑Oncology Expansion

Laverock Therapeutics, a UK‑based biotechnology company focused on programmable gene‑control technology, has been awarded two new innovation grants totaling in excess of £2.2 million to further develop its AI‑powered platform and expand its therapeutic pipeline beyond oncology.

The grants come from two leading innovation funds and will support the next generation of Laverock’s single‑cell, AI‑driven gene‑control platform, which is designed to deliver disease‑responsive advanced therapies.

A key focus of the new funding is pipeline expansion into non‑oncology indications, including the use of the company’s engineered macrophage‑based programs to modulate immune cell phenotypes and precisely control therapeutic payload expression in other disease areas.

This award adds to over £1.8 million in prior non‑dilutive funding that Laverock has received from UK Research and Innovation through programs such as Biomedical Catalyst and SMART business awards, underscoring continued support for the company’s platform in precision medicine and advanced therapies.